Clinicians can prescribe a GLP-1 and an SGLT2 inhibitor together. The American Diabetes Association says the combination may be considered for some people with type 2 diabetes who have established atherosclerotic cardiovascular disease or multiple risk factors. The recommendation applies to medicines with demonstrated cardiovascular benefit [4].
What a randomized combination trial found
Our comparison of GLP-1 and SGLT2 medicines explains why both classes are used in type 2 diabetes. DURATION-8 randomly assigned 695 adults whose blood sugar remained high on metformin to exenatide plus dapagliflozin or either medicine alone. At 28 weeks, HbA1c fell 0.4 percentage points more with the combination than with exenatide alone and 0.6 points more than with dapagliflozin alone [2].
Blood sugar was the trial’s primary outcome. The study was designed to answer a different question from whether taking both medicines prevents more heart attacks or kidney complications over time [2].
What the evidence says about heart and kidney outcomes
Studies of GLP-1 medicines and kidney disease provide context for what individual medicines can do. A separate review pooled 16 randomized trials to estimate outcomes with both medicines. Much of the combination evidence came from subgroups based on medicines participants were already taking. The original trials generally did not randomly assign that background treatment [1].
For the composite kidney outcome, the estimated risk ratio versus placebo was 0.63 with the combination (95% confidence interval 0.41–0.97) and 0.70 with an SGLT2 inhibitor alone (0.61–0.79). These two placebo comparisons do not establish an added kidney benefit from taking both [1].
What happened when patients filled prescriptions
The guide to filling a GLP-1 prescription explains why a prescription and a fill are measured separately. The PRECIDENTD feasibility study randomly assigned 173 insured adults with type 2 diabetes and cardiovascular disease or high cardiovascular risk to one of the two classes or both. By four months, 84% assigned one medicine filled it and 53% assigned both filled both. Over the full follow-up, which had a median of 10 months, those figures were 87% and 68%. This report examined access and use, rather than long-term heart or kidney outcomes [3].
What to discuss with the prescriber
Ask what each medicine is intended to treat and what monitoring you need. For example, the U.S. label for empagliflozin, an SGLT2 inhibitor, warns about dehydration from fluid loss and ketoacidosis. It also warns that taking empagliflozin with insulin can increase the risk of low blood sugar[5].